PolyActiva Commences Clinical Trial of Biodegradable Ocular Implant for Glaucoma

Clinical Trial Begins For PolyActiva Biodegradable Glaucoma Implant. PolyActiva Pty Ltd, a clinical-stage Australian biotechnology company, has recently received USD$12million in venture capital to fund its Phase 1 Clinical Trial which will evaluate the safety and tolerability of its PA5108 ocular implant designed to biodegrade after the treatment period.

VYZULTA™: A New FDA Approved Glaucoma Medication with Dual Action

On November 2, 2017, the FDA approved VYZULTA™ (latanoprostene bunod 0.024%) for the treatment of glaucoma. This newly available medication treats glaucoma in two distinct ways. One of these methods of protecting the optic nerve has already been available to those...

Simple Drops™ – Glaucoma Treatment Eye Drops

Simple Drops™ No more juggling multiple bottles Simplify with one Simple Drops™ Simplify Now What Are Simple Drops™ Simple Drops™ combine multiple medications into single drop bottles for glaucoma patient’s convenience. Simple Drops™ are NOT a new glaucoma drugs....

Next-Generation Glaucoma Medications and Surgeries

Part 12 of 14 of “Adjusting the Faucet or Opening the Drain – Currently Available Methods to Treat the Plumbing Problem of Open Angle Glaucoma” | A San Gabriel Valley Optometric Society (SGVOS) Continuing Education Dinner Event – 2 hours CE | Featured...

Pin It on Pinterest